Omalizumab Xolair®
The SHIKARI® Omalizumab portfolio provides one quantitative free-drug assay and two anti-omalizumab antibody assays for human serum or plasma. Each assay is presented according to its exact official product record.
Why Omalizumab is relevant to biological-drug monitoring research
Omalizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Omalizumab is a humanised IgG1 monoclonal antibody that binds free IgE at the Cε3 domain, reducing free IgE and down-regulating FcεRI expression. Source ↗
Approved Indications
EMA-authorised uses include severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in defined patients. EMA source ↗
Dose-Dependent Trough and Persistence
A universal trough target is not established. Regulatory data instead describe dose-proportional trough exposure and a long elimination half-life:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Omalizumab research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free omalizumab capable of binding IgE in human serum or plasma.
Sandwich-principle ELISA for quantitative determination of free anti-omalizumab antibodies in human serum or plasma; the assay includes a confirmation-reagent procedure.
Sandwich-principle ELISA for qualitative detection of anti-omalizumab antibodies in human serum or plasma, reported as reactive or non-reactive according to assay-specific interpretation criteria.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-OMA | OMA-FD-XOL | Quantitative | Free omalizumab | Human serum / plasma | 10 µL | 70 min | LOD 10 ng/mL; LOQ 30 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATO | OMA-QNS-XOL | Quantitative | Free anti-omalizumab antibodies | Human serum / plasma | 5 µL | 140 min | LOD 7.5 ng/mL; LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATO | OMA-QLS-XOL | Qualitative | Anti-omalizumab antibodies | Human serum / plasma | 5 µL | 140 min | Reactive / non-reactive | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarized from the current official product records. The standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Omalizumab Literature and Product-Use Records
Planning an Omalizumab research study?
Matrix Biotek can help identify the appropriate Omalizumab assay and prepare regional quotation and delivery information.